SUNNYVALE, CA--(Marketwire - September 05, 2012) - Spiracur Inc. today announced its inclusion on the NHS Supply Chain Framework Agreement for the provision of advanced wound care including its suite of negative pressure wound therapy (NPWT) solutions. In addition, the company announced that it has been granted reimbursement status for its SNaP® Wound Care System and listed on the U.K. Drug Tariff effective October 1, 2012.
The NHS Supply Chain Framework Agreement provides NHS trusts, government departments and private sector entities active in the UK healthcare sector, with access to a pre-selected list of approved suppliers, such as Spiracur Inc., to expedite the procurement process and potentially reduce costs.
Spiracur has created a new category of chronic and acute wound management solutions by combining the ease-of-use and cost savings of advanced wound care with the proven efficacy of NPWT. The company's innovative SNaP Wound Care System is a mechanically powered, ultraportable NPWT system encompassing proprietary spring technology that reduces air density within an enclosure. The springs stabilize in the presence of exudate so that a constant controlled amount of negative pressure is delivered to the wound bed. There is no electrical pump, enabling the SNaP System to operate in complete silence, and the device is small and light, weighing only 2.2 ounces/62 grams, and can be discreetly worn under clothing.
According to Ros Thomas, Deputy Head of Podiatry (ABM Trust) at Morriston Hospital in Swansea, Wales, the new device enables her team to offer more timely and effective treatment for patients suffering from lower extremity wounds. "Because it is so small and portable, it allows our patients to carry on their regular life style during therapy. Not only has quality of life for our patients improved during treatment with the SNaP System, clinical outcomes are excellent and we are seeing a reduction in costs as patients remain at their homes and not in hospital."
Spiracur's SNaP System is featured in the September 2012 Wounds International, an online practice-based journal for clinicians worldwide. The case report, co-authored by Teresa Awad, a tissue viability clinical nurse specialist from BUPA Cromwell Hospital in London, and Martyn Butcher, an independent tissue viability and wound care consultant, discuss the management of diabetic foot ulceration with the new, highly portable SNaP device.
"Positive wound healing outcomes are crucial in managing diabetic foot ulceration to avoid amputation," said Awad. "Negative Pressure Wound Therapy has proven to successfully enhance the healing of diabetic foot ulcerations, however, patients often need to deal with work pressures or certain lifestyle situations that may compromise their ability to heal. The novel SNaP System not only offers a new method of delivering NPWT, it allows patients to maintain their independence during therapy, thereby promoting effective wound healing."
A multitude of studies have been published supporting the SNaP Wound Care System as an effective alternative to powered NPWT, as well as a comparative Randomized Controlled Trial that proved the powerful, small device makes a positive difference in patients' quality of life. Recently, a prospective study to evaluate outcomes for the treatment of lower extremity diabetic, venous and mixed etiology leg wounds using the SNaP System commenced at Cardiff University School of Medicine in Wales. Principal investigator, Professor Keith Harding, Director, Institute for Translation, Innovation, Methodologies and Engagement (TIME) at the Cardiff University School of Medicine, is evaluating the efficacy of the SNaP system for treating difficult-to-heal lower extremity wounds and the impact on quality of life, reduction in pain and levels of exudate on up to 45 patients.
"Initial results from our UK study are quite promising," said Professor Harding. "It is our belief that the novel SNaP System will redefine how chronic wounds are treated here in the UK and globally as well. Wound treatment, especially lower extremity wounds, represent a significant cost burden to our system, however, the SNaP device provides us with an effective, less expensive wound care treatment option that addresses quality of life issues at the same time."
"We're thrilled to be selected as a vendor and awarded this important Framework Agreement by the NHS Supply Chain, where clinicians and patients now have access to a smaller, point-of-care solution for chronic wound treatment while saving money," said Gary Restani, president and chief executive officer, Spiracur Inc. "In addition, the Drug Tariff approval and the NHS Framework Agreement enable Spiracur to successfully treat patients in both the hospital and community settings, where there is increasing demand for our SNaP Wound Care System."
Spiracur obtained CE Mark for the SNaP Wound Care System in December of 2010.
About Spiracur Inc.
Spiracur Inc., headquartered in Sunnyvale, Calif., is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford University Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System for the treatment of chronic and acute wounds, is the result of patient and clinician feedback that current negative pressure wound therapies were too cumbersome. The company's ciSNaP™ Closed Incision System with proprietary controlled tension relief is designed to improve healing of high-risk surgical incisions. Both devices have been cleared by the U.S. Food & Drug Administration (FDA) and have received CE Mark approval. For more information, please visit http://spiracur.com.
Spiracur, Spiracur logo, and SNaP are registered trademarks, and ciSNaP is a trademark of Spiracur Inc.